Mediobanca Gets ECB Approval for Banca Generali Bid
The ECB's green light comes ahead of a meeting of Mediobanca's shareholders, due to be held Thursday, to vote on the offer and as it seeks to fend off a hostile takeover bid from Banca Monte dei Paschi di Siena BMPS 1.57%increase; green up pointing triangle.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
Villarreal set to break their transfer record
Villarreal set to break their transfer record originally appeared on The Sporting News Villarreal had a pretty good season last year as they finished 5th in La Liga last year and qualified for the Champions League. They started off their league campaign with a comfortable win against Real Oviedo and seem like they're on track for another good season. It seems like Villarreal are also expecting to have a good season as they are reportedly looking to improve their team by making a record signing. Renato Veiga to Villarreal Portuguese centre back Renato Veiga is heading to Villarreal on a seven year deal according to Fabrizio Romano. The club is set to pay Chelsea 29.5 million euros with a 40% sell-on clause that helped entice The Blues to complete the deal. The Portuguese centre back spent last season on loan at Juventus as he had struggled to settle in with Chelsea falling victim to the constant buying and selling of young talents that have become a staple of the new regime. Now, the talented centre back has the chance to settle down and develop and could become one of the best centre backs in the league. Villarreal Ambitions Villarreal fans should be ecstatic with this signing as their club is showing the ambition to build on last season and improve the team. They improve on their centre backs and should be able to make the starting eleven. It's the right move to make when the club is competing in multiple competitions this year. Villarreal will hope to make a significant push in Europe and push to be the best of the rest in La Liga.
Yahoo
40 minutes ago
- Yahoo
Iron Horse Acquisition Receives Clearance Pursuant to the Competition Act
Calgary, Alberta--(Newsfile Corp. - August 20, 2025) - Trican Well Service Ltd. (TSX: TCW) ("Trican") is pleased to announce that it has received clearance from the Competition Bureau, in the form of a No-Action Letter, with respect to the previously announced acquisition of all of the issued and outstanding shares of Iron Horse Energy Services ("Iron Horse") (the "Acquisition"). Iron Horse is a premium provider of fracturing and coiled tubing services in the Cardium, Charlie Lake, Mannville Stack, Viking, Montney and Shaunavon plays in the Western Canadian Sedimentary Basin. Under the terms of the Acquisition, Iron Horse shareholders will receive approximately $77.35 million in cash and approximately 33.76 million common shares of Trican. Following closing of the Acquisition, Tom Coolen, Chairman and CEO of Iron Horse, will be appointed to the board of directors of Trican. "We are delighted to have received a no-action letter from the Competition Bureau, completing a critical stage of our acquisition process. This acquisition augments our strategy and aligns with our long-term vision for growth and innovation in Canada. We look forward to better serving customers in all areas of the basin and creating meaningful value for our shareholders," said Brad Fedora, Trican's President and Chief Executive Officer. The Acquisition is expected to close on or about August 27, 2025, subject to the satisfaction or waiver of customary closing conditions and TSX listing approval of the common shares of Trican to be issued pursuant to the Acquisition. FORWARD-LOOKING STATEMENTS This document contains certain forward-looking information based on Trican's current expectations, estimates, projections and assumptions that were made by Trican in light of information available at the time the statement was made. Forward-looking information that addresses expectations or projections about the future, and other statements and information about Trican's strategy for growth, expected and future expenditures, costs, operating and financial results, future financing and capital activities are forward-looking statements. Forward-looking information in this press release is identified by the use of terms and phrases such as "anticipate", "achieve", "estimate", "expect", "intend", "plan", "planned", and other similar terms and phrases. This forward-looking information speaks only as of the date of this document, and we do not undertake to publicly update this forward-looking information except in accordance with applicable securities laws. This forward-looking information includes, among others: statements as to the proposed Acquisition; the anticipated benefits of the Acquisition; and the anticipated completion of the Acquisition and timing thereof. Forward-looking information is based on current expectations, estimates, projections and assumptions, which we believe are reasonable but which may prove to be incorrect. Readers are cautioned not to place undue reliance on forward-looking information as Trican's actual results may differ materially from those expressed or implied. Developing forward-looking information involves reliance on a number of assumptions and consideration of certain risks and uncertainties, some of which are specific to Trican and others that apply to the industry generally. Material factors or assumptions on which the forward-looking information in this press release is based include, among others, the successful closing of the Acquisition, including obtaining necessary stock exchange approvals and satisfying all other conditions to closing, within expected timelines. Additional information about assumptions, risk factors, uncertainties on which the forward-looking information is based and that could cause Trican's actual results to differ materially from any estimates or projects of future performance or results expressed or implied by such forward-looking statements are set forth under the section entitled "Risks Factors" in Trican's Annual Information Form for the year ended December 31, 2024, and under the section entitled "Business Risks" in Trican's management's discussion and analysis for the year ended December 31, 2024, which are each available on Trican's SEDAR+ profile at Readers are also referred to the risk factors and assumptions described in other documents filed by Trican from time to time with securities regulatory authorities. The reader is cautioned not to place undue reliance on forward looking information. ABOUT TRICAN Headquartered in Calgary, Alberta, Trican supplies oil and natural gas well servicing equipment and solutions to our customers through the drilling, completion and production cycles. Our team of technical experts provide state-of-the-art equipment, engineering support, reservoir expertise and laboratory services through the delivery of hydraulic fracturing, cementing, coiled tubing, nitrogen services and chemical sales for the oil and gas industry in Western Canada. Requests for further information should be directed to: Bradley P.D. FedoraPresident and Chief Executive Officer Scott E. MatsonChief Financial Officer Phone: (403) 266-02022900, 645 - 7th Avenue S.W. Calgary, Alberta T2P 4G8 Please visit our website at To view the source version of this press release, please visit Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
40 minutes ago
- Yahoo
Basilea Pharmaceutica Ltd (BPMUF) (H1 2025) Earnings Call Highlights: Strong Revenue Growth and ...
This article first appeared on GuruFocus. Global In-Market Sales Increase: Procemba sales increased by 24.8% for the 12-month period ending March 2025. Royalty Income Growth: 21.7% year-on-year increase in royalty income. Operating Result: Positive operating result of CHF 24 million for the first six months of 2025. Additional Funding: Secured $39 million in non-dilutive funding from BAA. Revenue: Total revenue of CHF 104 million, a 36% increase compared to the first half of 2024. Operating Expenses: CHF 55.7 million, mainly due to costs associated with the ongoing phase 3 program. Net Profit: CHF 15.8 million, compared to CHF 20.7 million in the first half of 2024. Net Cash Position: Positive net cash position of CHF 50.7 million as of June 30, 2025. Operating Cash Flow: Positive cash flow of CHF 23.1 million from operating activities. Debt Reduction: Reduced total debt by CHF 138.3 million from 2022 through June 30, 2025. Full Year 2025 Guidance: Total revenue expected to increase by about 8% to CHF 225 million. R&D Expenses: Projected to rise to CHF 105 million for 2025. Operating Profit Guidance: Expected operating profit of approximately CHF 50 million for 2025. Warning! GuruFocus has detected 5 Warning Signs with BPMUF. Is BPMUF fairly valued? Test your thesis with our free DCF calculator. Release Date: August 19, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Basilea Pharmaceutica Ltd (BPMUF) reported a strong financial performance for the first half of 2025, with a positive operating result of CHF 24 million. The company's leading commercial product, Procemba, saw a 24.8% increase in global in-market sales, contributing to a 21.7% year-on-year increase in royalty income. Basilea secured an additional $39 million in non-dilutive funding from BAA to support the development of its antifungal candidates. The company successfully launched its antibiotic Zayra in the US through a partnership with Innoviva Specialty Therapeutics. Basilea expanded its portfolio by in-licensing ceftibutin deaborbactam, a phase 3 ready novel oral antibiotic for complicated urinary tract infections. Negative Points The net profit for the first half of 2025 decreased to CHF 15.8 million from CHF 20.7 million in the first half of 2024, due to a one-time income tax benefit in the previous year. The company anticipates a 17% reduction in product revenue to about CHF 48 million year-on-year due to a decrease in product supply to Pfizer. R&D expenses are projected to rise to CHF 105 million, driven by the in-licensing transaction and associated costs. The phase 3 program for the newly in-licensed antibiotic is expected to start in approximately 18 months, which may delay potential revenue contributions. Currency fluctuations, particularly the devaluation of the US dollar against the Swiss franc, impacted financial results. Q & A Highlights Q: Why is there an 18-month delay before starting the phase 3 trial for the newly in-licensed antibiotic? Does this relate to securing additional funding? A: David Veitch, CEO, clarified that the delay is not due to funding issues. The 18-month period is necessary for regulatory interactions with health authorities and operational setup. Marc Engelhardt, CMO, added that the studies require a large patient supply, which takes time to prepare. Q: How does the expanded access program for fosmanogepix impact regulatory approval, given the large number of patients involved? A: Marc Engelhardt, CMO, explained that the data from the expanded access program could serve as confirmatory evidence in an NDA filing, provided it meets FDA guidelines for completeness and context. Q: How does the new oral antibiotic fit into the treatment landscape for complicated UTIs, which is dominated by IV treatments? A: Marc Engelhardt, CMO, stated that the oral antibiotic will serve both as an initial empirical therapy and a step-down treatment from IV antibiotics, offering flexibility in hospital and outpatient settings. Q: Why is there expected softness in product revenues in the second half of the year? A: Adesh Kaul, CFO, explained that the fluctuation is due to product delivery schedules and initial supplies related to the US launch and other markets, rather than any underlying weakness. Q: What factors could accelerate enrollment in the fosmanogepix phase 3 program? A: Marc Engelhardt, CMO, mentioned that geographic analysis and increased sponsor engagement at underperforming sites could enhance enrollment rates. Q: Can you provide details on the sales and marketing infrastructure for Zevtera's US rollout? A: David Veitch, CEO, highlighted that Innoviva Specialty Therapeutics has extensive experience in launching antibiotics, with a comprehensive US coverage including sales, medical affairs, and access teams. Q: How does the oral antibiotic compare to GSK's oral carbapenem in clinical development for complicated UTIs? A: Marc Engelhardt, CMO, noted that while there are similarities in trial design, the new antibiotic offers advantages in spectrum and dosing frequency, potentially capturing significant market share. Q: How is Crescemba performing in the APAC region, and how will it mitigate the impact of the 2027 loss of exclusivity? A: Adesh Kaul, CFO, reported strong growth in APAC, particularly in Japan, where exclusivity extends beyond 2027, contributing to sustained revenue despite upcoming patent expirations. For the complete transcript of the earnings call, please refer to the full earnings call transcript. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
